Comparative Pharmacology
Head-to-head clinical analysis: ECONAZOLE NITRATE versus M ZOLE 7 DUAL PACK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ECONAZOLE NITRATE versus M ZOLE 7 DUAL PACK.
ECONAZOLE NITRATE vs M-ZOLE 7 DUAL PACK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Econazole nitrate, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase (CYP51), blocking ergosterol synthesis, disrupting fungal cell membrane integrity and function.
M-ZOLE 7 DUAL PACK contains miconazole, an imidazole antifungal that inhibits fungal lanosterol 14α-demethylase (CYP51), blocking ergosterol synthesis, disrupting fungal cell membrane integrity, and increasing permeability, leading to cell death.
Topical: Apply a thin layer to affected area twice daily (morning and evening). Vaginal: One applicatorful (150 mg) intravaginally at bedtime for 3 days. Rectal candidiasis: One 150 mg suppository rectally at bedtime for 3 days.
Adults: One vaginal tablet (containing 500 mg metronidazole and 150 mg miconazole nitrate) inserted vaginally once daily at bedtime for 7 days.
None Documented
None Documented
Terminal elimination half-life approximately 8-10 hours; clinical relevance: supports twice-daily topical dosing for sustained antifungal effect.
Terminal half-life approximately 48–72 hours. Prolonged in renal impairment (up to 72–120 hours in ESRD), requiring dose adjustment.
Primarily hepatic metabolism; <1% unchanged in urine; 30-45% in feces as metabolites; minimal biliary excretion.
Primarily renal (80% unchanged drug, 20% as metabolites); biliary/fecal excretion is minimal (<5%).
Category A/B
Category C
Antifungal
Antifungal